c-Jun N-terminal kinase inhibitor II (SP600125) activates Müllerian inhibiting substance type II receptor-mediated signal transduction

Endocrinology

Volumn 149, Issue 1, 2008, Pages 108-115

  Renlund, Nina ^a   Pieretti Vanmarcke, Rafael ^a   O'Neill, Francis H ^a   Zhang, LiHua ^a   Donahoe, Patricia K ^a   Teixeira, Jose ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BONE MORPHOGENETIC PROTEIN; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 9; MUELLERIAN INHIBITING FACTOR; MUELLERIAN INHIBITING FACTOR RECEPTOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG POTENTIATION; FEMALE; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR GENE; SCREENING; SIGNAL TRANSDUCTION;

ANIMALS; ANTHRACENES; ANTI-MULLERIAN HORMONE; BONE MORPHOGENETIC PROTEINS; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; ENZYME INHIBITORS; FEMALE; JNK MITOGEN-ACTIVATED PROTEIN KINASES; OVARIAN NEOPLASMS; PROMOTER REGIONS (GENETICS); RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION;

EID: 37549068957     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0529     Document Type: Article

References (47)

1. Teixeira J, Maheswaran S, Donahoe PK 2001 Mullerian inhibiting substance: an instructive developmental hormone with diagnostic and possible therapeutic applications. Endocr Rev 22:657-674
2. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J, di Clemente N 2000 Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. J Biol Chem 275:27973-27978
3. Visser JA, Olaso R, Verhoef-Post M, Kramer P, Themmen AP, Ingraham HA 2001 The serine/threonine transmembrane receptor ALK2 mediates Mullerian inhibiting substance signaling. Mol Endocrinol 15:936-945
4. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM, Donahoe PK 2001 Mullerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression. Mol Endocrinol 15:946-959
5. Jamin SP, Arango NA, Mishina Y, Hanks MC, Behringer RR 2002 Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nature genetics 32:408-410
6. Zhan Y, Fujino A, MacLaughlin DT, Manganaro TF, Szotek PP, Arango NA, Teixeira J, Donahoe PK 2006 Mullerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mullerian duct regression. Development 133:2359-2369
7. Massague J, Wotton D 2000 Transcriptional control by the TGF-beta/Smad signaling system. EMBO J 19:1745-1754
8. Gupta V, Carey JL, Kawakubo H, Muzikansky A, Green JE, Donahoe PK, MacLaughlin DT, Maheswaran S 2005 Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model. Proc Natl Acad Sci USA 102:3219-3224
9. Segev DL, Ha TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughlin DT, Donahoe PK, Maheswaran S 2000 Mullerian inhibiting substance inhibits breast cancer cell growth through an NFκB-mediated pathway. J Biol Chem 275:28371-28379
10. Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha TU, Maheswaran S 2003 Mullerian inhibiting substance induces NFκB signaling in breast and prostate cancer cells. Mol Cell Endocrinol 211:43-49
11. Tran TT, Segev DL, Gupta V, Kawakubo H, Yeo G, Donahoe PK, Maheswaran S 2006 Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-κB-dependent Smad-independent mechanism. Mol Endocrinol 20:2382-2391
12. Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK 2003 Mullerian inhibiting substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci USA 100:15601-15606
13. Renaud EJ, MacLaughlin DT, Oliva E, Rueda BR, Donahoe PK 2005 Endometrial cancer is a receptor-mediated target for Mullerian inhibiting substance. Proc Natl Acad Sci USA 102:111-116
14. Stephen AE, Pearsall LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT 2002 Highly purified Mullerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8:2640-2646
15. Pieretti-Vanmarcke R, Donahoe PK, Pearsall LA, Dinulescu DM, Connolly DC, Halpern EF, Seiden MV, MacLaughlin DT 2006 Mullerian inhibiting substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer. Proc Natl Acad Sci USA 103:17426-17431
16. Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT 2006 Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo. Clin Cancer Res 12:1593-1598
17. Bennett BL, Sasaki DT, Murray BW, O'Leary EC, Sakata ST, Xu W, Leisten JC, Motiwala A, Pierce S, Satoh Y, Bhagwat SS, Manning AM, Anderson DW 2001 SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc Natl Acad Sci USA 98:13681-13686
18. Hibi M, Lin A, Smeal T, Minden A, Karin M 1993 Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7:2135-2148
19. Clark GJ, Westwick JK, Der CJ 1997 p120 GAP modulates Ras activation of Jun kinases and transformation. J Biol Chem 272:1677-1681
20. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME 1995 Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:1326-1331
21. Ennis BW, Fultz KE, Smith KA, Westwick JK, Zhu D, Boluro-Ajayi M, Bilter GK, Stein B 2005 Inhibition of tumor growth, angiogenesis, and tumor cell proliferation by a small molecule inhibitor of c-Jun N-terminal kinase. J Pharmacol Exp Ther 313:325-332
22. Wang B, Tsukada J, Higashi T, Mizobe T, Matsuura A, Mouri F, Sawamukai N, Ra C, Tanaka Y 2006 Growth suppression of human mast cells expressing constitutively active c-kit receptors by JNK inhibitor SP600125. Genes Cells 11:983-992
23. Korchynskyi O, ten Dijke P 2002 Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. J Biol Chem 277:4883-4891
24. Logeart-Avramoglou D, Bourguignon M, Oudina K, Ten Dijke P, Petite H 2006 An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoterluciferase construct. Anal Biochem 349:78-86
25. Teixeira J, He WW, Shah PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, Maclaughlin DT, Donahoe PK 1996 Developmental expression of a candidate Mullerian inhibiting substance type II receptor. Endocrinology 137:160-165
26. Donahoe PK, Ito Y, Hendren WH 1977 A graded organ culture assay for the detection of Mullerian inhibiting substance. J Surg Res 23:141-148
27. Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK, MacLaughlin DT 2002 New approaches for high-yield purification of Mullerian inhibiting substance improve its bioactivity. J Chromatogr B Analyt Technol Biomed Life Sci 766:89-98
28. Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
29. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC 2003 Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 63:1389-1397
30. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T 2005 Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63-70
31. Behringer RR, Finegold MJ, Cate RL 1994 Mullerian-inhibiting substance function during mammalian sexual development. Cell 79:415-425
32. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer RR 1996 Genetic analysis of the Mullerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes Dev 10:2577-2587
33. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM 1998 Direct binding of Smad3 and Smad4 to critical TGFβ-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100
34. Hazzalin CA, Le Panse R, Cano E, Mahadevan LC 1998 Anisomycin selectively desensitizes signalling components involved in stress kinase activation and fos and jun induction. Mol Cell Biol 18:1844-1854
35. Lemonnier J, Ghayor C, Guicheux J, Caverzasio J 2004 Protein kinase C-independent activation of protein kinase D is involved in BMP-2-induced activation of stress mitogen-activated protein kinases JNK and p38 and osteoblastic cell differentiation. J Biol Chem 279:259-264
36. Suzuki A, Ghayor C, Guicheux J, Magne D, Quillard S, Kakita A, Ono Y, Miura Y, Oiso Y, Itoh M, Caverzasio J 2006 Enhanced expression of the inorganic phosphate transporter Pit-1 is involved in BMP-2-induced matrix mineralization in osteoblast-like cells. J Bone Miner Res 21:674-683
37. Atfi A, Djelloul S, Chastre E, Davis R, Gespach C 1997 Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in transforming growth factor β-mediated signaling. J Biol Chem 272:1429-1432
38. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG 2003 Transforming growth factor-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene 22:4314-4332
39. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA 2001 TGF-κB-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 3:708-714
40. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K 2002 Activations of ERK1/2 and JNK by transforming growth factor β negatively regulate Smad3-induced alkaline phosphatase activity and mineralization in mouse osteoblastic cells. J Biol Chem 277:36024-36031
41. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ, Haasch DL, Wang S, Clampit JE, Johnson EF, Lubben TH, Stashko MA, Olejniczak ET, Sun C, Dorwin SA, Haskins K, Abad-Zapatero C, Fry EH, Hutchins CW, Sham HL, Rondinone CM, Trevillyan JM 2006 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem 49:3563-3580
42. Heo YS, Kim SK, Seo CI, Kim YK, Sung BJ, Lee HS, Lee JI, Park SY, Kim JH, Hwang KY, Hyun YL, Jeon YH, Ro S, Cho JM, Lee TG, Yang CH 2004 Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125. EMBO J 23:2185-2195
43. Ha TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S 2000 Müllerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism. J Biol Chem 275:37101-37109
44. Bhalla KN 2003 Microtubule-targeted anticancer agents and apoptosis. Oncogene 22:9075-9086
45. Zhang X, Ling MT, Wang X, Wong YC 2006 Inactivation of Id-1 in prostate cancer cells: a potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 118:2072-2081
46. Wang TH, Chan YH, Chen CW, Kung WH, Lee YS, Wang ST, Chang TC, Wang HS 2006 Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways. Oncogene 25:4857-4866
47. Tan G, Heqing L, Jiangbo C, Ming J, Yanhong M, Xianghe L, Hong S, Li G 2002 Apoptosis induced by low-dose paclitaxel is associated with p53 upregulation in nasopharyngeal carcinoma cells. Int J Cancer 97:168-172